<p>BALB/cJ mice implanted with 7,500 4T1-Luc2GFP cells were treated with the maximal tolerated dose (MTD) of doxorubicin, the dose shown not to result in any gross toxicity to the animal but shown to result in a small but insignificant loss in weight over the course of the experiment; or with carrier (5% Pharmasolve and 5% Solutol HS in saline), or with injectable saline as control once a week after visible primary tumor formation, for five weeks. (<b>A</b>) Flowchart indicating timing of cell implantation, doxorubicin treatments, and experimental determinations. (<b>B</b>) Tumors volume (mm<sup>3</sup>) over time measured by calipers. (<b>C</b>) End weight of tumors (mg), (<b>D</b>) Lung micrometastases. (<b>E</b>) Lung large micrometastases. (<b>F</b>) Lung macrometastases. Data representative of two independent experiments <i>n</i> = 15 mice for first experiment, and <i>n</i> = 10 mice for second experiment. Tumor volumes were calculated using the ellipsoidal method, volume (mm<sup>3</sup>) = 0.52 × length × width<sup>2</sup>. Data are mean ± <i>SEM</i> and a two way ANOVA/Tukey post-test was performed (*p<0.05 and **p<0.01).</p
